In colorectal cancer/melanoma, the ALKBH5 inhibitor ALK-04 downregulated expression of VEGFA and TGFβ1, thus inhibiting angiogenesis and enhancing efficacy of anti–PD-1 therapy [32]. The gene discussed is ALK; the disease is colorectal cancer.